Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The Senior Special Adviser to the President on Industrialisation at the African Development Bank, Prof. Banji ...

Dofu Cat makes four litter varieties: cereal, tofu, multi-cat, and coffee bean. The multi-cat variety is made with bean fiber ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences' stock rose 9% after completing ... so I'll avoid delving into this type of operation. This subject is made even more difficult to opine on/trace by the fact that the DoJ is ...

Our society is plagued by an artificial limitation of choices, which largely accounts for the persistence of poverty and ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...

The SEC said that Cassava made misleading statements about a clinical trial of its Alzheimer’s disease drug. Cassava in the settlement neither confirmed nor denied the charges. Study data was ...

The misleading statements were made in September 2020 about the results of a phase two clinical trial for Cassava's purported drug treatment for Alzheimer's, the SEC said. Cassava's shares dropped ...

26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences ... that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...